Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash from Financing Activities (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Cash from Financing Activities readings, the most recent being $1.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 131.48% year-over-year to $1.3 million, compared with a TTM value of $8.9 million through Dec 2025, down 94.05%, and an annual FY2025 reading of $8.9 million, down 94.05% over the prior year.
  • Cash from Financing Activities hit $1.3 million in Q4 2025 for Apellis Pharmaceuticals, up from $793000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $391.1 million in Q1 2023, with the low at -$15.9 million in Q4 2022.
  • Median Cash from Financing Activities over the past 5 years was $2.3 million (2021), compared with a mean of $65.5 million.
  • The largest YoY upside for Cash from Financing Activities was 22982.35% in 2022 against a maximum downside of 204.62% in 2022.
  • Year by year, Cash from Financing Activities stood at $384.0 million in 2021, then plummeted by 104.15% to -$15.9 million in 2022, then surged by 75.46% to -$3.9 million in 2023, then fell by 2.22% to -$4.0 million in 2024, then soared by 131.48% to $1.3 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $1.3 million, $793000.0, and $6.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.